If you are choosing between pterostilbene and resveratrol based on human evidence, resveratrol is the better-supported choice. Pterostilbene is a close chemical relative with a persuasive pharmacokinetic rationale, but the famous “about 80% versus 20% bioavailability” comparison comes from rats. We did not identify a human head-to-head trial that measured oral bioavailability or health outcomes for both compounds in the same participants.
Pterostilbene still deserves scientific interest. In its main standalone human trial, 250 mg/day lowered systolic and diastolic blood pressure versus placebo. When the two pterostilbene-only dose groups were analyzed together, LDL cholesterol increased by 17.1 mg/dL over 6–8 weeks.2 Resveratrol has a much larger human trial record, including recent systematic and umbrella reviews that report population-specific benefits.1112
Pterostilbene vs resveratrol: the comparison that matters
Resveratrol and pterostilbene are stilbenes, a family of plant polyphenols. Resveratrol is commonly studied as trans-resveratrol, the predominant and more studied geometric isomer. Pterostilbene is its naturally dimethylated analog: two of resveratrol’s hydroxyl groups are replaced with methoxy groups.14
That structural change makes pterostilbene more lipophilic and more resistant to some metabolic pathways in experimental models.1415 The mistake is jumping from that chemistry to “pterostilbene is better for humans.” The clinical evidence is not at that point.
CELLSHE EVIDENCE MAP
Resveratrol vs pterostilbene, ranked by what has actually been tested in humans
| Question | Resveratrol | Pterostilbene | CELLSHE interpretation |
|---|---|---|---|
| Direct human head-to-head comparison? | No trial identified comparing both compounds in the same people. | No trial identified comparing both compounds in the same people. | The winner cannot be declared from a human comparative trial because that trial has not been identified. |
| The famous oral bioavailability figure | About 20% in the 2011 rat comparison. | About 80% in the same rat comparison. | Useful animal pharmacokinetics, not a human absorption percentage. |
| Human pharmacokinetics | Multiple primary studies plus a 2025 meta-analysis of 84 oral administrations.510 | Much smaller human pharmacokinetic record. A 2025 open-label crossover study measured pterostilbene pharmacokinetics in healthy volunteers, but did not compare it with resveratrol.16 | Resveratrol’s human absorption and metabolism are far better characterized. |
| Human clinical evidence | A 2024 systematic review identified 194 purified-resveratrol clinical studies.11 | Standalone evidence remains small, with one main 80-person metabolic trial and a 2025 30-person pilot.24 | Evidence maturity strongly favors resveratrol. |
| Positive human signals | A 2026 umbrella review found high-certainty evidence for several modest, population-specific cardiometabolic outcomes.12 | The 2014 trial found lower systolic and diastolic blood pressure at 250 mg/day.2 | Both have human signals, but the volume and replication differ greatly. |
| Key safety signal | Generally well tolerated in many trials, with dose-dependent gastrointestinal effects and drug-interaction considerations covered in human studies.911 | When the two pterostilbene-only dose groups were analyzed together, LDL cholesterol increased by 17.1 mg/dL versus placebo.2 | Pterostilbene’s smaller evidence base makes this LDL finding important to the decision. |
| Evidence-led choice today | Better supported. | Promising, but less established in humans. | Choose resveratrol when human evidence depth is the deciding criterion. |
Sources: Kapetanovic et al. 2011; Riche et al. 2013 and 2014; Otsuka et al. 2025; Peer et al. 2025; Szymkowiak et al. 2025; Brown et al. 2024; Sun et al. 2026.123410111216
Where the “80% vs 20% bioavailability” claim actually comes from
The headline is real, but the population matters. In 2011, National Cancer Institute researchers compared equimolar oral doses of resveratrol and pterostilbene in male rats. Across the study conditions, pterostilbene showed several-fold higher absolute oral bioavailability, summarized by the authors as roughly 80% versus 20% for resveratrol.1
The rats received 50 or 150 mg/kg/day of resveratrol and equimolar 56 or 168 mg/kg/day doses of pterostilbene. Oral dosing was tested after one dose and after 14 daily doses. Those are pharmacokinetic data from an animal model, not human supplement absorption percentages.
CELLSHE ANALYSIS
How a rat pharmacokinetic result became a human-sounding supplement claim
- Original finding: pterostilbene had higher absolute oral bioavailability than resveratrol in an equimolar rat study.1
- Common shorthand: “pterostilbene is 80% bioavailable and resveratrol is 20% bioavailable.” The species is often dropped.
- Human evidence check: resveratrol has direct human pharmacokinetic studies, but we did not identify a human trial that measured both compounds head to head.
- Useful conclusion: pterostilbene has a credible pharmacokinetic hypothesis. It does not yet have a demonstrated human superiority result.
Resveratrol is absorbed. Rapid metabolism is the bigger issue.
“Poor absorption” and “low bioavailability” are often treated as the same thing. They are not.
In a radiolabeled human study, at least 70% of a 25 mg oral resveratrol dose was absorbed in six volunteers. Unchanged resveratrol in plasma remained very low because sulfate and glucuronide metabolism was rapid.5
Later human studies confirmed rapid metabolism across much larger doses.678 A 2025 meta-analysis then synthesized 84 oral resveratrol administrations from clinical trials across doses from 25 to 5,000 mg. Free resveratrol exposure rose with dose, but the authors also found substantial methodological heterogeneity.10
Why this distinction matters: low concentrations of unchanged resveratrol in blood do not mean the compound was barely absorbed. They reflect extensive metabolism. Human clinical outcomes should be judged from human outcome trials, not inferred from one plasma percentage.
The same caution applies to half-life claims. Published estimates change with dose, formulation, route, analyte and sampling design. A 2025 open-label crossover study measured pterostilbene Cmax, Tmax, AUC, mean residence time and half-life in healthy volunteers.16 It did not compare pterostilbene with resveratrol, so it cannot establish a human head-to-head half-life advantage.
What pterostilbene has actually done in oral human studies
Pterostilbene’s oral human evidence is no longer limited to a single paper, but it is still compact. For standalone clinical outcomes and short-term safety, the most informative work comes from one 80-person cohort with elevated total or LDL cholesterol, plus a 2025 pilot in 30 healthy men.234
CELLSHE DATA
The standalone oral human pterostilbene evidence at a glance
| Study | Population | Dose and duration | What was measured | Main finding |
|---|---|---|---|---|
| Riche et al. 20142 | 80 adults with total cholesterol ≥200 mg/dL and/or LDL ≥100 mg/dL | 100 or 250 mg/day pterostilbene; a separate pterostilbene plus grape-extract arm; 6–8 weeks | Lipids, blood pressure, weight | When the two pterostilbene-only dose groups were analyzed together, LDL increased by 17.1 mg/dL versus placebo. At 250 mg/day, systolic blood pressure fell 7.8 mmHg and diastolic pressure fell 7.3 mmHg versus placebo. |
| Riche et al. 20133 | The same 80-person cohort | Same randomized groups; 6–8 weeks | Hepatic, renal, glucose and reported adverse events | No significant major or self-reported adverse reactions and no adverse hepatic, renal or glucose signal in the measured markers. |
| Otsuka et al. 20254 | 30 healthy men | 10 or 100 mg/day; 12 weeks | Blood biochemistry, blood microRNA, safety | No adverse events were reported. Changes were reported in selected blood microRNAs, which are biomarkers rather than clinical outcomes. |
| Peer et al. 202516 | Healthy volunteers | 250 mg pterostilbene in single- and multi-dose conditions, alone and with niacin; one week | Cmax, Tmax, AUC, mean residence time and half-life | Human pterostilbene pharmacokinetics were measured, but the study did not include a resveratrol comparator. |
Sources: Riche et al. 2013 and 2014; Otsuka et al. 2025; Peer et al. 2025.23416
The LDL result deserves weight because it came from the main pterostilbene monotherapy trial. It should not erase the blood-pressure finding from that same study. The sensible reading is that early human data contain both a potentially useful signal and a cardiovascular risk-marker signal that needs independent replication.
The short-term tolerability results are also useful. They support that the tested doses did not produce major measured safety problems over 6–12 weeks in those participants.34 They do not answer long-term safety at supplemental doses.
Why the deeper resveratrol evidence changes the choice
Resveratrol is not merely “older” or “more popular.” It has been studied in humans across a much wider set of populations, doses and outcomes. A 2024 systematic review identified 194 clinical studies using purified resveratrol across at least 24 indications.11
The newer evidence is also more useful than a simple study count. A 2026 umbrella review evaluated 45 systematic reviews and 68 health outcomes. High-certainty evidence supported modest reductions in waist circumference, total cholesterol among overweight adults, and blood pressure among people with type 2 diabetes.12 Those findings are population-specific, but they show why human outcome evidence matters more than a theoretical absorption advantage.
Resveratrol also has claims that deserve tighter interpretation. A 2025 meta-analysis of 11 randomized trials found no significant effect on SIRT1 gene expression, protein expression or serum levels.13 Resveratrol does not need a simplified “sirtuin activator” story to have a legitimate research base. Its strongest case is the human evidence itself.
For a deeper outcome-by-outcome review, see CELLSHE’s guide to resveratrol benefits. For the molecule, sources and metabolism, start with what resveratrol is.
Resveratrol, trans-resveratrol and “pure resveratrol” are not interchangeable label terms
This distinction matters when the comparison moves from molecules to supplements. Resveratrol names the compound itself and is also used as a broad ingredient term on many supplement labels. Trans-resveratrol is the predominant and more studied geometric isomer in human research. “Pure resveratrol” is not a precise scientific dose unless the label or certificate states both purity and isomer content.
A label can therefore state a large resveratrol-complex number while delivering a smaller amount of trans-resveratrol. CELLSHE’s trans-resveratrol explainer covers the chemistry in detail.
Label example: CELLSHE Resveratrol 600 states 600 mg of resveratrol complex per capsule, standardized to 50% trans-resveratrol. That equals about 300 mg of trans-resveratrol per capsule. The complex amount and the trans-resveratrol amount are different numbers.
Which one should you choose?
Choose resveratrol when your priority is the depth of human evidence. That is the clearest evidence-led decision today. Pterostilbene has attractive chemistry and strong animal pharmacokinetics, but it has not yet shown superior absorption or superior health outcomes in a direct human comparison.
If you choose resveratrol, look for the stated trans-resveratrol amount rather than relying on a large total-extract number. If LDL cholesterol is already a concern, the main pterostilbene trial deserves attention. The two monotherapy dose groups showed a 17.1 mg/dL LDL increase when analyzed together.2
Can you take pterostilbene and resveratrol together?
Products that combine stilbenes or include pterostilbene with other ingredients exist, but that does not establish that adding pterostilbene improves outcomes compared with resveratrol alone. We did not identify a robust human trial designed to answer that comparison directly.
What pterostilbene dose has been studied in humans?
Standalone oral human studies in this evidence set used 10, 100 and 250 mg/day. The main 80-person trial also included 100 mg/day pterostilbene alongside grape extract, while the 2025 pharmacokinetic study used 250 mg pterostilbene in single- and multi-dose conditions.2416 These are research doses, not a universal dosage recommendation. CELLSHE’s separate resveratrol dosage guide explains why trial dose, label dose and personal dose are different questions.
What about side effects?
Pterostilbene’s short-term human studies reported no major measured adverse-event pattern, while the LDL increase remains the most important standalone metabolic signal.23 Resveratrol has a much larger human safety record, and controlled studies have also examined drug-metabolizing enzyme interactions.119 CELLSHE reviews those data separately in resveratrol side effects.
The evidence favors resveratrol today
Pterostilbene may eventually prove to have a useful human pharmacokinetic advantage. The chemistry gives researchers a good reason to test that idea. The evidence available today does not justify treating the rat 80% versus 20% result as a human superiority verdict.
Resveratrol is the stronger choice when the standard is human evidence: its pharmacokinetics are better characterized, its clinical trial record is far larger, and current evidence syntheses identify several population-specific benefits. Pterostilbene remains an interesting comparator with a smaller human record that includes both lower blood pressure and an LDL increase in its main metabolic trial.
References
- Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. 2011. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemotherapy and Pharmacology. PMID: 21116625. PubMed.
- Riche DM, Riche KD, Blackshear CT, et al. 2014. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evidence-Based Complementary and Alternative Medicine. PMID: 25057276. PubMed.
- Riche DM, McEwen CL, Riche KD, et al. 2013. Analysis of safety from a human clinical trial with pterostilbene. Journal of Toxicology. PMID: 23431291. PubMed.
- Otsuka K, Kuriki D, Kamachi K, Tanaka A, Matsuoka R. 2025. Analysis of the Effects of Short-Term Pterostilbene Intake on Healthy Participants: A Pilot Study. Journal of Nutritional Science and Vitaminology. PMID: 40024751. PubMed.
- Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK. 2004. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. PMID: 15333514. PubMed.
- Boocock DJ, Faust GE, Patel KR, et al. 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention. PMID: 17548692. PubMed.
- Vaz-da-Silva M, Loureiro AI, Falcão A, et al. 2008. Effect of food on the pharmacokinetic profile of trans-resveratrol. International Journal of Clinical Pharmacology and Therapeutics. PMID: 19000554. PubMed.
- la Porte C, Voduc N, Zhang G, et al. 2010. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol in healthy human subjects. Clinical Pharmacokinetics. PMID: 20528005. PubMed.
- Chow HHS, Garland LL, Hsu CH, et al. 2010. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prevention Research. PMID: 20716633. PubMed.
- Szymkowiak I, Marcinkowska J, Kucińska M, Regulski M, Murias M. 2025. Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data. Phytotherapy Research. PMID: 39557444. PubMed.
- Brown K, Theofanous D, Britton RG, et al. 2024. Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences. PMID: 38255828. PubMed.
- Sun JN, Yang R, Fang L, et al. 2026. Effects of resveratrol supplementation on multiple health outcomes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Nutrition Journal. PMID: 41987155. PubMed.
- Mansouri F, Feliziani G, Bordoni L, Gabbianelli R. 2025. Impact of Resveratrol Supplementation on Human Sirtuin 1: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Journal of the Academy of Nutrition and Dietetics. PMID: 40158656. PubMed.
- Wang P, Sang S. 2018. Metabolism and pharmacokinetics of resveratrol and pterostilbene. BioFactors. PMID: 29315886. PubMed.
- Nagarajan S, Mohandas S, Ganesan K, Xu B, Ramkumar KM. 2022. New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects. Molecules. PMID: 36234852. PubMed.
- Peer AH, Abbas S, Ullah I, Shakeel F, Ullah R, Khan MA. 2025. Pharmacokinetic Evaluation of Niacin and Pterostilbene in Single and Multi-Doses in Healthy Subjects. Jordan Journal of Pharmaceutical Sciences. 18(1):217–229. DOI: 10.35516/jjps.v18i1.2710. DOI.
